Story perspectives

Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer

6/7/2026

Summary

Story summary

Revolution Medicines announced on May 31 2026 that daraxonrasib doubled overall survival for metastatic pancreatic cancer in Phase 3.
Daraxonrasib is an oral drug that blocks KRAS signaling by binding cyclophilin A, the first targeted therapy for undruggable tumors.
Over 86 percent of patients had a skin rash, with stomatitis, diarrhea, nausea and vomiting also common.
Revolution will seek FDA and global approval, requesting expedited review and targeting market launch within months if cleared.

1 of 1

Story summary

Revolution Medicines announced on May 31 2026 that daraxonrasib doubled overall survival for metastatic pancreatic cancer in Phase 3.
Daraxonrasib is an oral drug that blocks KRAS signaling by binding cyclophilin A, the first targeted therapy for undruggable tumors.
Over 86 percent of patients had a skin rash, with stomatitis, diarrhea, nausea and vomiting also common.
Revolution will seek FDA and global approval, requesting expedited review and targeting market launch within months if cleared.